CEO Todd Zavodnick (Dermavant)
February 18, 2021 08:25 AM EST
R&D

With long-term da­ta in hand, Vivek Ra­maswamy's Der­ma­vant team dash­es to the goal line with top­i­cal pso­ri­a­sis con­tender

Nicole DeFeudis

Editor

Months af­ter tout­ing pos­i­tive da­ta from two piv­otal Phase II­Is, Vivek Ra­maswamy’s Der­ma­vant team is back with long-term da­ta to back its pso­ri­a­sis can­di­date …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times